Sign up to get updates from us
Ryvu’s lead asset, discovered-inhouse is RVU120, a CDK8/19 inhibitor with activity in both hematologic and solid tumor cancers currently undergoing multicenter, international testing for AML and TNBC, respectively. With data reported as recently as EHA 2022, pivotal phase II testing will commence in early 2023. As for the platform, with a dual focus on immune-oncology and synthetic lethality—Galapagos wants to take it for a spin, as does Merck, and Ryvu just inked a deal with Exelixis. Give a listen to Ryvu CEO Pawel Przewiezlikowski for all the details…
